Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial-Reference-Cited by-同舟云学术

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Published:2018-09 Issue:9 Volume:19 Page:1170-1179
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

van den Bent Martin J,Klein Martin,Smits Marion,Reijneveld Jaap C,French Pim J,Clement Paul,de Vos Filip Y F,Wick Antje,Mulholland Paul J,Taphoorn Martin J B,Lewis Joanne,Weller Michael,Chinot Olivier L,Kros Johan M,de Heer Iris,Verschuere Tina,Coens Corneel,Golfinopoulos Vassilis,Gorlia Thierry,Idbaih Ahmed

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas;Weller;Lancet Oncol,2017

2. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse;Yung;J Clin Oncol,1999

3. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response;Taal;Neuro Oncol,2011

4. Temozolomide chemotherapy in recurrent oligodendroglioma;van den Bent;Neurology,2001

5. Chemotherapy for anaplastic oligodendroglioma;Cairncross;J Clin Oncol,1994

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 1p19q co-deletion is an independent prognostic factor in glioma with TERT promoter mutations;2024-08-17

2. Targeting inhibition of prognosis-related nicotinamide metabolism genes, including poly (ADP-ribose) polymerase 9 (PARP-9) attenuates glioma progression;2024-07-19

3. The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials;Frontiers in Medicine;2024-07-02

4. Bevacizumab for Glioblastoma Multiforme: A Literature Review;JAP Academy Journal;2024-06-01

5. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas;European Journal of Cancer;2024-05